JMP Securities Downgrades Cadence Pharmaceuticals (CADX) to Underperform
More News related to CADX
- Oppenheimer Downgrades Cadence Pharmaceuticals (CADX) to Perform
- Cadence Pharma (CADX) Dec volatility at 63, Feb at 111 into FDA goal date
- FDA Extends Cadence Pharmaceuticals (CADX) PDUFA Date by Three Months
- Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
- Cadence Pharmaceuticals (CADX) Up Ahead of Tomorrow's PDUFA Date
More News related to Downgrades
- Wells Fargo Downgrades Regency Centers (REG) to Market Perform; Reducing 2009-2010E FFO/Share
- Goldman Sachs Upgraded US REITS to Neutral; Ups BKD, AVB, GGWPQ, Downgrades KIM
- Collins Stewart Downgrades Genzyme (GENZ) to Hold; Await Additional Execution and Clarity on Troubled Fronts
- Davenport Downgrades Nokia (NOK) to Neutral
- Sidoti & Co Downgrades Innophos Holdings (IPHS) to Neutral
JMP Securities downgrades Cadence Pharmaceuticals (Nasdaq: CADX) from Market Perform to Underperform.
To see more analyst ratings on CADX Click Here.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
